Ranking Profile - Aptevo Therapeutics Inc

Introduction

Aptevo Therapeutics Inc (Aptevo) is a clinical-stage biotechnology company that develops and commercializes oncology and hematology therapeutics. Its pipeline products include APVO436 for the treatment of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML); ALG.APV-527 for potential treatment of a broad spectrum of cancers including mesothelioma, cervical, prostate, renal, breast, non-small-cell-lung, gastric, colorectal and bladder cancers; APVO603 for solid tumors. Aptevo has received Orphan Drug Designation (ODD) for its pipeline product APVO436 from the US FDA for the treatment of acute myelogenous leukemia (AML). The pipeline immuno-oncology candidates are built on its proprietary Adaptir and Adaptir-Flex platform technologies. Aptevo is headquartered in Seattle, Washington, the US.